Single-center retrospective review of standard versus minimal monitoring for hepatitis C direct-acting antiviral therapy
Authors:
- 12 October 2024
- journal article
- review article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 65 (1) , 102265
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Reengagement strategies for hepatitis C patients lost to follow-up: A randomized clinical trialHepatology Communications, 2023
- Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United StatesJAMA Network Open, 2022
- A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trialThe Lancet Gastroenterology & Hepatology, 2022
- Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?Telemedicine and e-Health, 2021
- Impact of COVID-19 on global HCV elimination effortsJournal of Hepatology, 2021
- Hepatitis C Virus Elimination by 2030: Conquering Mount ImprobableClinical Liver Disease, 2020
- Loss to follow‐up in the hepatitis C care cascade: A substantial problem but opportunity for micro‐eliminationJournal of Viral Hepatitis, 2020
- Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialJournal of Hepatology, 2020
- Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled TrialOpen Forum Infectious Diseases, 2020
- Evaluation of the Aspartate Aminotransferase/Platelet Ratio Index and Enhanced Liver Fibrosis Tests to Detect Significant Fibrosis Due to Chronic Hepatitis CJournal of Clinical Gastroenterology, 2014